You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Metastatic disease (M1)/stage 4 NSCLC 
Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized. 
Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course 
Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding) 
Prior chemotherapy, radiotherapy, or surgery for NSCLC 
Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer. Note: Patients with prior surgically-cured malignancies [eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc] are not excluded; however, sponsor approval must be obtained before patient is randomized. 
Presence or history of dysphagia or conditions predisposing to dysphagia (eg, uncontrolled gastroesophageal reflux disease [GERD], dyspepsia, etc) 
History of pancreatitis 
Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment 
Previous treatment on this study or with a fibroblast growth factor 
Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) 
Pregnant or breastfeeding women 
Known sensitivity to E. coli derived products 
Compromised ability of the patient to give written informed consent and/or to comply with study procedures 
Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable 
Unwilling or unable to complete the patient reported outcome (PRO) questionnaires 
Psychological, social, familial, or geographical reasons that would prevent regular follow-up
{"Condition": ["pericardial effusion", "Pregnant", "surgically-cured malignancies", "sensitivity", "Compromised ability", "toxicity", "pancreatitis", "sero-positive for human immunodeficiency virus (HIV)", "gastroesophageal reflux disease", "dyspepsia", "malignancy", "(M1)/stage 4", "sero-positive for hepatitis C virus (HCV)", "GERD", "dysphagia", "Metastatic disease NSCLC", "non-melanomatous skin cancer", "Pleural effusion", "sero-positive for hepatitis B virus (HBV)", "conditions predisposing to dysphagia", "NSCLC", "breastfeeding"], "Device": ["investigational device"], "Drug": ["chemotherapy", "products", "investigational product", "fibroblast growth factor"], "Measurement": ["hepatitis B virus (HBV)", "CT", "computed tomography scan", "hepatitis C virus (HCV)", "PET", "ultrasound", "positron emission tomography", "human immunodeficiency virus (HIV)"], "Mood": [], "Multiplier": ["any part of"], "Negation": ["other than", "are not"], "Observation": ["History of", "Plan to remove the tumor surgically", "Refusal to", "history of"], "Person": ["women"], "Procedure": ["posterior spinal cord shielding", "radiotherapy", "surgery", "Shielding", "treatment"], "Qualifier": ["unresolved", "esophagus", "invasive", "E. coli derived", "uncontrolled"], "ReferencePoint": ["completion of treatment"], "Scope": ["investigational product/device", "positron emission tomography [PET], computed tomography [CT] scan or ultrasound", "uncontrolled gastroesophageal reflux disease [GERD], dyspepsia", "dysphagia or conditions predisposing to dysphagia", "give written informed consent and/or to comply with study procedures", "chemotherapy, radiotherapy, or surgery"], "Temporal": ["Four weeks or less since completion of treatment", "Previous", "Prior", "before completing the protocol chemo/radiotherapy course", "previous", "during the past 3 years"], "Value": ["greater than 100 ml in volume", "sero-positive"], "Visit": []}